This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.
Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–758.
Kanda Y, Komatsu Y, Akahane M, Kojima S, Asano-Mori Y, Tada M et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 2005; 79: 821–827.
Tchirkov A, Kanold J, Combaret V, Philip I, Kwiatkowski F, Malet P et al. Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection. Bone Marrow Transplant 1999; 24: 229–230.
Reynolds CP . Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 2004; 8 (Suppl 5): 56–66.
Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 1999; 78: 418–425.
Fleischhack G, Hasan C, Graf N, Mann G, Bode U . IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998; 102: 647–655.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marabelle, A., Paillard, C., Tchirkov, A. et al. Graft-versus-tumour effect in refractory metastatic neuroblastoma. Bone Marrow Transplant 39, 809–810 (2007). https://doi.org/10.1038/sj.bmt.1705681
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705681
This article is cited by
-
αβ T-cell-depleted haploidentical hematopoietic cell transplantation and zoledronate/interleukin-2 therapy in children with relapsed, high-risk neuroblastoma
Bone Marrow Transplantation (2019)
-
Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l’Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire
Bone Marrow Transplantation (2013)
-
Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial
Bone Marrow Transplantation (2011)
-
Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN
Bone Marrow Transplantation (2011)
-
Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model
Bone Marrow Transplantation (2008)